Tools
Stock profile

ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

ARWR · Latest close $43.11 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$43.11
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
1 / 1
vs previous quarter
Trimmed / exited
2
vs previous quarter

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 1 fund adding, and 2 funds trimming or exiting versus the previous quarter. Latest close $43.11 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Avoro Capital Advisors · Deerfield Management · Baker Bros. Advisors — 5 tracked funds hold ARWR. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

Celcuity Inc. (CELC) · Mirum Pharmaceuticals, Inc. (MIRM) · Praxis Precision Medicines, Inc. (PRAX) · XENON PHARMACEUTICALS INC (XENE) · Dianthus Therapeutics, Inc. /DE/ (DNTH) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Avoro Capital Advisors8.31%11,355,555ADDED (+6.1%) Q3 filed Nov 16
Deerfield Management1.18%1,389,055TRIMMED (-11.7%) Q3 filed Nov 16
Baker Bros. Advisors0.81%1,992,783HELD Q3 filed Nov 16
Edgewood Management0.02%25,000HELD Q3 filed Nov 12
Polen Capital Management<0.01%6,612NEW Q3 filed Nov 13
RTW Investments——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -46.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

89.596.812024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding505 of 8,857 filers
Long-only filers among them498
Change vs 2026 Q1+74 net · 480 entered · 406 exited
Shares reported, all filers119,163,036
Reported value, all filers$9.7B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$829.4M
Net income · FY2025$-1.6M
Total assets · FY2025$1.4B
Shares outstanding141,254,467
Market cap (at latest close)$6.1B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 30, 2026.

Short interest

Shares short · Oct 15, 202610,959,276
Share of shares outstanding7.76%
Days to cover5.36

Shares short at recent settlements — Jul 31, 2026: 9.7M · Aug 14, 2026: 9.2M · Aug 31, 2026: 9.4M · Sep 15, 2026: 9.3M · Sep 30, 2026: 10.8M · Oct 15, 2026: 11.0M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 30, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 671 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 30, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 18, 2026Adeoye OlukotunDirector2,000$173.9KAug 18, 2026SEC filing
Aug 18, 2026Michael PerryDirector11,600$1.0MAug 18, 2026SEC filing
May 19, 2026Daniel ApelOfficer13,095$934.2KApr 22, 2026SEC filing
May 19, 2026Hongbo LuOfficer2,970$228.3KMay 12, 2026SEC filing
May 19, 2026James HamiltonOfficer10,000$750.0KApr 23, 2026SEC filing
May 12, 2026Hongbo LuOfficer2,970$228.3KMay 12, 2026SEC filing
Apr 23, 2026James HamiltonOfficer10,000$750.0KApr 23, 2026SEC filing
Apr 22, 2026Daniel ApelOfficer13,095$934.2KApr 22, 2026SEC filing
Mar 5, 2026James HamiltonOfficer10,000$641.9KMar 5, 2026SEC filing
Jan 5, 2026James HamiltonOfficer40,164$2.5MJan 5, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Aug 15, 2025SCHEDULE 13D/A+115.9% (close Aug 18, 2025 → Nov 17, 2026)

Reference close is the first trading day after the filing (Aug 18, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026Avoro Capital Advisors LLCSC 13G/A13,823,3839.6%Jun 30, 2026SEC filing
Jul 31, 2026Vanguard Portfolio ManagementSC 13G/A6,384,9034.5%Jun 30, 2026SEC filing
Jul 27, 2026BlackRock, Inc.SC 13G/A14,232,54510.1%Jun 30, 2026SEC filing
May 6, 2026FMR LLCSC 13G7,349,106.755.2%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G7,081,2935.0%Mar 31, 2026SEC filing
Apr 28, 2026Vanguard Portfolio ManagementSC 13G7,269,9575.2%Mar 31, 2026SEC filing
Apr 24, 2026BlackRock, Inc.SC 13G/A17,104,08412.2%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Jan 21, 2026BlackRock, Inc.SC 13G/A20,323,22115.0%Dec 31, 2025SEC filing
Aug 15, 2025Sarepta Therapeutics, Inc.SC 13D/A00.0%Aug 13, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

This stock does not currently pass any tracked screen.

Also held by the tracked funds that hold ARWR — ranked by lift, the co-holding pattern described in Methodology: Celcuity Inc. (CELC) · Mirum Pharmaceuticals, Inc. (MIRM) · Praxis Precision Medicines, Inc. (PRAX) · XENON PHARMACEUTICALS INC (XENE) · Dianthus Therapeutics, Inc. /DE/ (DNTH) · STRUCTURE THERAPEUTICS INC (GPCR) · Taysha Gene Therapies, Inc. (TSHA) · REVOLUTION MEDICINES INC (RVMD).

Filings audit: every filing lens on ARROWHEAD PHARMACEUTICALS, INC. (ARWR), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Nov 12, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Nov 4, 20261.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial ObligationSEC filing
Aug 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Celcuity Inc. (CELC) · Filings audit: every filing lens on ARROWHEAD PHARMACEUTICALS, INC. (ARWR), scored · Practice timing on ARWR

One email a week: the week’s new filings and research. Subscribe free

← ARW  ·  ARX →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.